The Effect Of Glycemic Control On Malondialdehyde, Glutathione Peroxidase, Glutathione And Paraoxonase

Type 2 Diabetes Mellitus Clinical Trial

Official title:

Malondialdehyde And Antioxidant Levels In Chronic Periodontitis Patients With Type 2 Diabetes Mellitus Under Different Stages Of Metabolic Control

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01467674
• Other study ID #: 1721-D-08
• Status: Completed
• Phase: N/A
• First received: November 1, 2011
• Last updated: November 8, 2011
• Start date: January 2008
• Est. completion date: May 2009

Study information

• Verified date: November 2011
• Source: Suleyman Demirel University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The aim of this study was to investigate the impact of glycemic control on clinical periodontal status, levels of malondialdehyde (MDA), glutathione peroxidase (GSH-Px), reduced glutathione (GSH) and paraoxonase (PON) activity in gingival crevicular fluid (GCF) and blood samples of type 2 diabetes mellitus (T2DM) patients with chronic periodontitis (CP).

Description:

Reactive oxygen species (ROS) are products of normal cellular metabolism and play beneficial role in physiological functions. Overproduction of ROS and/or deficiency of enzymatic or non-enzymatic antioxidants, termed as oxidative stress, is involved in many pathological conditions such as Diabetes mellitus (DM) and chronic periodontitis (CP).

Several researches revealed that DM, with many determinants such as level of glycemic control, stands as a strong risk factor for periodontal diseases. On the other side, periodontal diseases induce an elevated chronic inflammatory state and exacerbated insulin resistance.

In the present study, the investigators examined the effect of glycemic control level on clinical periodontal status, levels of MDA, GSH-Px, GSH and PON activity in gingival crevicular fluid and blood samples of CP patients with T2DM.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: May 2009
• Est. primary completion date: May 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• to present T2DM diagnosis by an endocrinologist for at least the past 5 years

• diagnosis of CP was based on the clinical and radiographic criteria proposed by the 1999 World Workshop for Classification of Periodontal Diseases and Conditions

Exclusion Criteria:

• pregnancy

• lactation

• current smoking or smoking within the past 2 years, periodontal therapy in the previous 6 months

• antibiotic and/or antimicrobial therapies in the previous 3 months

• existence of serious diabetic complications or any pathology such as haemoglobinopathy which would affect haemoglobin profile

• diagnosis of another major medical pathology, middle or upper-level obesity according to WHO classification

• current anti-hyperlipidemic therapy

• non-T2DM patients with abnormal values of glucose and lipid metabolism parameters, major medical pathology and family history of DM

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Chronic Periodontitis
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Periodontitis
• Type 2 Diabetes Mellitus

Locations

Country	Name	City	State
Turkey	Suleyman Demirel University	Isparta

Sponsors (1)

Lead Sponsor	Collaborator
Suleyman Demirel University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HbA1c	Level of Metabolic Control	One Year	No
Secondary	Clinical Periodontal Status	Periodontal indices evaluating clinical periodontal health status	One Year	No

External Links

•   I